Solbinsiran (LY3561774)

· Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Solbinsiran (LY3561774), covering 2026-04-22 to 2026-04-22. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia [Phase 2]